Alnylam Pharmaceuticals
ALNY
#954
Rank
$19.44 B
Marketcap
$154.39
Share price
1.59%
Change (1 day)
-18.96%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$4.11

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$4.11. In 2022 the company made an earnings per share (EPS) of -$9.29 a decrease over its 2021 EPS that were of -$7.20.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$4.11-55.76%
2022-$9.2929.03%
2021-$7.20-3.36%
2020-$7.45-8.48%
2019-$8.147.67%
2018-$7.5639.74%
2017-$5.4112.94%
2016-$4.7938.84%
2015-$3.45-32.88%
2014-$5.14259.44%
2013-$1.43-31.25%
2012-$2.0852.94%
2011-$1.3630.77%
2010-$1.04-8.77%
2009-$1.1478.13%
2008-$0.64-70.78%
2007-$2.1999.09%
2006-$1.10-43.88%
2005-$1.96-82.33%
2004-$11.09-59.23%
2003-$27.21

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.74-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$3.18-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
$37.36-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$7.83 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.69-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.27-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.00-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
-$1.70-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA